SCHEMBL12128269

SCHEMBL12128269

CC(C)[Si](C(C)C)(C(C)C)n1ccc2ccc(Nc3cccc(C(=O)N(C)C)c3)nc21

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ EPHB4 P54760 2/20 0.42
▸ NEK2 P51955 1/20 0.39
▸ FYN P06241 2/20 0.36
▸ SYK P43405 1/20 0.36
▸ MAPT P10636 2/20 0.36
▸ NPC1 O15118 1/20 0.36
▸ RAB9A P51151 1/20 0.36
▸ ROCK1 Q13464 2/20 0.36
▸ CAMK1D Q8IU85 1/20 0.35
▸ CYP1A2 P05177 1/20 0.35
▸ CYP2C9 P11712 1/20 0.35
▸ CLK4 Q9HAZ1 1/20 0.35
▸ ADORA2A P29274 1/20 0.35
▸ MAPK9 P45984 1/20 0.34
▸ MAPK10 P53779 1/20 0.34
▸ BRD4 O60885 1/20 0.34
▸ EP300 Q09472 1/20 0.34
▸ CREBBP Q92793 1/20 0.34
▸ PIK3CA P42336 1/20 0.34
▸ TP53 P04637 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12128272 0.87 FTO (0.44) NEK2SYKMAPTCYP1A2CYP2C9
SCHEMBL12128987 0.72 NEK2 (0.47) EPHB4NEK2FYNMAPTNPC1
SCHEMBL12285206 0.67 EPHB4 (0.46) EPHB4NEK2FYNNPC1RAB9A
SCHEMBL12127689 0.66 APP (0.38) SYK
SCHEMBL8343055 0.64 HTT (0.45) NEK2FYN
SCHEMBL15386428 0.63 HTT (0.44) NEK2
SCHEMBL20888459 0.63 HTT (0.44) NEK2NPC1
SCHEMBL13208760 0.62 CYP1A2 (0.48) EPHB4NEK2MAPTCYP1A2CYP2C9
SCHEMBL28284716 0.62 MEN1 (0.51) NPC1RAB9A
SCHEMBL7406706 0.61 MEN1 (0.55) CYP2C9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20160158242-A1 Novel Compounds for the Treatment of Diseases Associated with Amyloid or Amyloid-Like Proteins AC IMMUNE SA (CH) 2016-06-09 — — US disclosed
US-9221812-B2 Compounds for the treatment of diseases associated with amyloid or amyloid-like proteins AC IMMUNE SA (CH) 2015-12-29 — — US disclosed
US-20110280808-A1 Novel Compounds for the Treatment of Diseases Associated with Amyloid or Amyloid-Like Proteins AC IMMUNE, S.A. (CH) 2011-11-17 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110280808-A1 Novel Compounds for the Treatment of Diseases Associated with Amyloid or Amyloid-Like Proteins APP, PSEN1, PSEN2 EPHB4 1014/4885NEK2 4309/4885FYN 1958/4885
US-20160158242-A1 Novel Compounds for the Treatment of Diseases Associated with Amyloid or Amyloid-Like Proteins APP, PSEN1, PSEN2 EPHB4 1014/4885NEK2 4309/4885FYN 1958/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback